National Comprehensive Cancer Network



About NCCN

NCCN Flash Update: NCCN Guidelines for Non-Hodgkin's Lymphomas Updated

Flash Update Sent November 30, 2010

NCCN has published updates to the NCCN Guidelines™ for Non-Hodgkin’s Lymphomas. These NCCN Guidelines are currently available as Version 1.2011.

Significant updates include:

  • For chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), guidelines for CLL with and without a deletion of 11q and the corresponding suggested treatment regimens were added.
  • For follicular lymphoma, the category designation for first-line therapy with bendamustine + rituximab was changed from a category 2A to a category 1. In addition, the category designation for first-line consolidation or extended dosing with rituximab maintenance was changed from a category 2B to a category 1, and “up to 2 y” was added as a qualifier.
  • For mycosis fungoides/Sézary syndrome with evidence of folliculotropic or large cell transformation, systemic chemotherapy regimens were added.
  • New guidelines were developed for Extranodal NK/T-cell Lymphoma, nasal type and Post-transplant Lymphoproliferative Disorders, and a Principles of Radiation Therapy section was added.


For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved